Proactive Pipeline Intelligence.
Intelligent notifications and synthesis when news breaks about the programs you care about.
Pfizer Amplifies Oncology Focus Post-Seagen Acquisition, Targets ADCs and Biologics for Future Growth
High - Deal - 2024
Pfizer has unveiled its strategic vision for its Oncology organization, emphasizing the integration of Seagen's capabilities and a robust pipeline with multiple potential blockbusters by 2030.
| Source Type | Content | Open |
|---|---|---|
| Press Release | By 2030, the company anticipates 8 or more potential blockbusters. |
Pfizer's ABRYSVO RSV Vaccine Demonstrates Sustained Efficacy in Older Adults and Expands Indications
High - Deal - 2024
Pfizer's ABRYSVO, a bivalent RSV vaccine, has shown consistent high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose in adults 60 years or older.
No sources available
High relevance updates, based on your interests.
Intelligent notifications and synthesis when news breaks about the programs you care about.
DH-003 Likely Halted
Inbox
Maven Bio
1 minute ago
to me
DH-003 has been removed from Daring Health’s pipeline graphic on their website.
What to know: This paired with a prolonged PH 2 (recruiting for 2.5 years without update) likely indicates the program has been paused.
Pipeline Webpage monitoring
We monitor the pipeline webpage of biopharma companies you care about -- so you don’t have to.
DH-004 PH2 Enrolled
Inbox
Maven Bio
1 minute ago
to me
Daring Health has announced enrollment (n=59) is complete for DH-004’s PH 2 study
What to know: What to know: Enrollment took ~6 months and based on the protocol, we should expect a read-out on the study in Q4 2024
"We are encouraged by the full enrollment of our Phase 2 trial ahead of our projected timeline, a strong testament to the potential that new therapies could bring for patients felt by the healthcare providers participating in this trial" Daring Health's Chief Medical Officer (Open Press Release)
"protocol entails a 3-month enrollment phase followed by a 4-month observation period"
Press Releases and News
We scan industry news and let you know when something important happens on the topics you’ve selected
Don't be caught off guard again.
It's hard to stay on top of pipeline activity, so let us help.
Give custom instructions
Personalize your alerts by providing high-level instructions on your requirements
Monitor specific programs
Select specific programs you want to monitor
Configure alert frequency
Ditch the clutter - easily adjust the frequency of email alerts
Monitor companies
Select from a set of 20K+ biopharma companies to monitor
Calibrate alerting thresholds
Only want to know about major updates? No problem, easily adjust your alert thresholds
Monitor key phrases
Prefer to monitor a given target or technology? Create a keyword monitor in seconds.